Citigroup’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-857,481
| Closed | -$29.5M | – | 7812 |
|
|
2020
Q3 | $29.5M | Buy |
857,481
+773,452
| +920% | +$16.5M | 0.02% | 707 |
|
|
2020
Q2 | $1.4M | Buy |
84,029
+31,425
| +60% | +$534K | ﹤0.01% | 3190 |
|
|
2020
Q1 | $758K | Sell |
52,604
-9,284
| -15% | -$237K | ﹤0.01% | 3462 |
|
|
2019
Q4 | $2.07M | Sell |
61,888
-27,480
| -31% | -$768K | ﹤0.01% | 2928 |
|
|
2019
Q3 | $1.87M | Buy |
89,368
+64,545
| +260% | +$1.32M | ﹤0.01% | 2948 |
|
|
2019
Q2 | $517K | Buy |
24,823
+15,193
| +158% | +$313K | ﹤0.01% | 4393 |
|
|
2019
Q1 | $215K | Sell |
9,630
-60,616
| -86% | -$1.43M | ﹤0.01% | 5034 |
|
|
2018
Q4 | $1.68M | Buy |
70,246
+51,382
| +272% | +$1.33M | ﹤0.01% | 2841 |
|
|
2018
Q3 | $515K | Buy |
18,864
+112
| +0.6% | +$3.17K | ﹤0.01% | 4244 |
|
|
2018
Q2 | $504K | Sell |
18,752
-5,621
| -23% | -$172K | ﹤0.01% | 4094 |
|
|
2018
Q1 | $776K | Sell |
24,373
-16,914
| -41% | -$595K | ﹤0.01% | 3509 |
|
|
2017
Q4 | $1.56M | Buy |
41,287
+14,407
| +54% | +$465K | ﹤0.01% | 2902 |
|
|
2017
Q3 | $667K | Buy |
26,880
+3,986
| +17% | +$85.9K | ﹤0.01% | 3811 |
|
|
2017
Q2 | $471K | Buy |
22,894
+9,330
| +69% | +$178K | ﹤0.01% | 4041 |
|
|
2017
Q1 | $294K | Sell |
13,564
-35,743
| -72% | -$733K | ﹤0.01% | 4328 |
|
|
2016
Q4 | $1.01M | Buy |
49,307
+46,511
| +1,663% | +$951K | ﹤0.01% | 3685 |
|
|
2016
Q3 | $42K | Sell |
2,796
-300
| -10% | -$4.05K | ﹤0.01% | 5793 |
|
|
2016
Q2 | $33K | Sell |
3,096
-6,107
| -66% | -$83K | ﹤0.01% | 5845 |
|
|
2016
Q1 | $124K | Buy |
9,203
+4,380
| +91% | +$68.3K | ﹤0.01% | 5508 |
|
|
2015
Q4 | $89K | Buy |
4,823
+4,466
| +1,251% | +$82.6K | ﹤0.01% | 5466 |
|
|
2015
Q3 | $9K | Buy |
+357
| New | +$8.35K | ﹤0.01% | 6505 |
|
Citigroup's AIMT Position: Q4 2020 in Review
Citigroup sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 857,481 shares — an estimated $29.5M sold.
Citigroup first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $29.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Citigroup reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Citigroup sold 857,481 Aimmune Therapeutics shares in Q4 2020, an estimated $29.5M.
- Citigroup first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Citigroup's Aimmune Therapeutics position peaked at $29.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Citigroup's 13F filing for Q4 2020, filed 11 Feb 2021.